Because TSLP overproduction is triggered by skin-barrier defects and faithfully mirrors the severity of these defects [15], our data emphasize that an early and aggressive treatment of the underlying skin-barrier defects in AD-prone patients [10],[11] may be more beneficial in preventing asthma than treating the outbreaks of AD lesions [6]. The gene discussed is TSLP; the disease is asthma.